Atopic dermatitis (AD) is a chronic, multifactorial, inflammatory skin disease that can have a
negative impact on patient quality of life (QoL). Moderate to severe forms frequently require …

Atopic dermatitis (AD) is a chronic inflammatory skin disease mediated by the helper T cell
type 2 cytokines interleukin 4 (IL-4) and/or IL-13. 1 Dupilumab is a monoclonal antibody that …

202 I CUTIS® WWW. MDEDGE. COM/CUTIS at 2-and then 4-week intervals. After 2 weeks
of treatment, methotrexate was increased to 10 mg once weekly. His asthma was carefully …

Atopic dermatitis (AD) is one of the most common chronic skin conditions worldwide,
affecting more than 15% of children and 2% of adults. 1 Although AD has traditionally been …

Figure 1 Clinical markers during dupilumab treatment of our HIV-positive patient. Evolution
of SCORing Atopic Dermatitis (SCORAD) and Dermatology Life Quality Index (DLQI) scores …

DEAR EDITOR, Cytokine inhibition through biological and targeted drugs has revolutionized
the treatment of many chronic immune-mediated inflammatory diseases over the past …

Some atopic dermatitis (AD) patients have facial redness that is resistant to dupilumab, 1
even though the lesions on other parts of their body are responsive to treatment. The reason …

Facial and neck erythema secondary to dupilumab use is a side effect not reported in clinical
trials; however, it has been reported aftermarket initially in adults and most recently in …

1 Roche L, Donncha EL, Murphy M. TikTokTM and dermatology: promises and pearls. Clin
Exp Dermatol 2021; 46: 737–9. 2 Zheng DX, Ning AY, Levoska MA et al. TikTok, TM teens …

PK received travel grants and lecture fees from Sanofi-Genzyme. JCS received lecture fees,
honoraria for advisory boards, and a non-restricted scientific grant from Sanofi-Genzyme. RT …